Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
Palanques-Pastor T, Megías-Vericat JE, Martínez P, López Lorenzo JL, Cornago Navascués J, Rodriguez Macias G, Cano I, Arnan Sangerman M, Vidriales Vicente MB, Algarra Algarra JL, Foncillas MÁ, Herrera P, Botella Prieto C, Vives S, Figuera Álvarez Á, Cuevas Palomares L, Sobas M, Contento Gonzalo A, Cuello García R, Amutio Diez ME, De Miguel Llorente D, Navas Elorza B, Bergua Burgues JM, Bernal Del Castillo T, Mateos Rodríguez MC, de Cabo López E, Franco Villegas AC, García Boyero R, Escolano Escobar C, Seri Merino C, Cervero C, Roldán Pérez A, Hermosín Ramos L, Cervera Calvo M, Olave MT, Villafuerte Gutiérrez P, de Laiglesiai A, Serrano J, Najera Irazu MJ, Piñana JL, Sanz MÁ, Martínez-López J, Montesinos P. Palanques-Pastor T, et al. Leuk Lymphoma. 2021 Dec;62(12):2928-2938. doi: 10.1080/10428194.2021.1948031. Epub 2021 Jul 22. Leuk Lymphoma. 2021. PMID: 34292118
Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain.
Arenaza A, Diez R, Esteve J, Di Nicolantonio R, Gostkorzewicz J, Martínez C, Martínez Llinàs D, Martinez-Lopez J, Montesinos P, Moure-Fernández A, Sierra J, Vinent JL. Arenaza A, et al. Clinicoecon Outcomes Res. 2019 Nov 13;11:683-694. doi: 10.2147/CEOR.S222879. eCollection 2019. Clinicoecon Outcomes Res. 2019. PMID: 32009807 Free PMC article.
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality.
Martínez-López J, Mateos MV, Encinas C, Sureda A, Hernández-Rivas JÁ, Lopez de la Guía A, Conde D, Krsnik I, Prieto E, Riaza Grau R, Gironella M, Blanchard MJ, Caminos N, Fernández de Larrea C, Senin MA, Escalante F, de la Puerta JE, Giménez E, Martínez-Barranco P, Mateos JJ, Casado LF, Bladé J, Lahuerta JJ, de la Cruz J, San-Miguel J. Martínez-López J, et al. Blood Cancer J. 2020 Oct 19;10(10):103. doi: 10.1038/s41408-020-00372-5. Blood Cancer J. 2020. PMID: 33077708 Free PMC article.
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D, Serrano J, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón JA, García-Boyero R, Rodríguez-Medina C, López-Pavía M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Colorado M, Sayas MJ, Algarra L, Vidriales MB, Rodríguez-Macías G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Ramos F, Rodríguez-Gutiérrez JI, Costilla-Barriga L, Labrador J, Boluda B, Rodríguez-Veiga R, Martínez-López J, Sanz MA, Montesinos P. Martínez-Cuadrón D, et al. Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. Epub 2020 Oct 19. Leukemia. 2021. PMID: 33077867
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B, Vidriales MB, Sempere A, Tarín F, Colado E, Benavente C, Cedena MT, Sánchez J, Caballero-Velazquez T, Cordón L, Garces JJ, Simoes C, Martínez-Cuadrón D, Bernal T, Botella C, Grille S, Serrano J, Rodríguez-Medina C, Algarra L, Alonso-Domínguez JM, Amigo ML, Barrios M, García-Boyero R, Colorado M, Pérez-Oteyza J, Pérez-Encinas M, Costilla-Barriga L, Sayas MJ, Pérez O, González-Díaz M, Pérez-Simón JA, Martínez-López J, Sossa C, Orfao A, San Miguel JF, Sanz MÁ, Montesinos P; PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Paiva B, et al. Leukemia. 2021 Aug;35(8):2358-2370. doi: 10.1038/s41375-021-01126-3. Epub 2021 Feb 1. Leukemia. 2021. PMID: 33526859
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.
Martínez-López J, Mustjoki S, Porkka K, Klisovic RB, Wolf D, Busque L, Hernández-Boluda JC, Swanink R, Martin Regueira P, Lipton JH. Martínez-López J, et al. Leuk Lymphoma. 2021 Aug;62(8):2040-2043. doi: 10.1080/10428194.2021.1889536. Epub 2021 Mar 2. Leuk Lymphoma. 2021. PMID: 33653205 Clinical Trial. No abstract available.
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, Vives S, Algarra JL, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Paiva B, Barragán E, Prosper F, Sanz MÁ, Martínez-López J, Montesinos P, On Behalf Of The Programa Para El Estudio de la Terapeutica En Hemopatias Malignas Pethema Cooperative Study Group. Ayala R, et al. Cancers (Basel). 2021 May 18;13(10):2458. doi: 10.3390/cancers13102458. Cancers (Basel). 2021. PMID: 34070172 Free PMC article.
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M, Martínez-Sánchez P, Rodríguez-Arbolí E, García-Boyero R, Rodríguez-Medina C, Martínez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Espadana A, Sayas MJ, Algarra L, Vidriales MB, Vasconcelos G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Chillón MC, Rodríguez-Gutiérrez JI, Calasanz MJ, Labrador J, López JA, Boluda B, Rodríguez-Veiga R, Martínez-López J, Barragán E, Sanz MA, Montesinos P, On Behalf Of The Pethema Group. Martínez-Cuadrón D, et al. Cancers (Basel). 2022 Jun 6;14(11):2817. doi: 10.3390/cancers14112817. Cancers (Basel). 2022. PMID: 35681796 Free PMC article.
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castaño-Bonilla T, Barragán E, Sargas C, Sanz A, Algarra L, Herrera-Puente P, García-Boyero R, Barrios M, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Serrano-López J, Martínez-López J, Sayas-Lloris MJ, Olave MT, Riaza-Grau R, Castillo TB, Larrayoz MJ, Amigo R, Jiménez-Velasco A, Sánchez J, Ayala R, Blas C, Lainez D, Serrano-López J, Sanz MA, Alonso-Domínguez JM, Montesinos P. Castaño-Bonilla T, et al. Dis Markers. 2022 Aug 23;2022:3132941. doi: 10.1155/2022/3132941. eCollection 2022. Dis Markers. 2022. PMID: 36051360 Free PMC article.
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao C, Sánchez-García J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Pérez-Simón JA, Calbacho M, Alonso-Domínguez JM, Labrador J, Tormo M, Amigo ML, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz MJ, Gomez-Casares T, García-Sanz R, Sanz MA, Martínez-López J, Montesinos P. Ayala R, et al. Cancers (Basel). 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799. Cancers (Basel). 2022. PMID: 36497281 Free PMC article.
750 results